Advertisement

A case of double-refractory multiple myeloma with both the IgH-MMSET fusion protein and the congenital abnormality t(11;22)

  • Rikio SuzukiEmail author
  • Takayuki Warita
  • Yoshihiko Nakamura
  • Yuka Kitamura
  • Yasuyuki Aoyama
  • Yoshiaki Ogawa
  • Hiroshi Kawada
  • Kiyoshi AndoEmail author
Case Report
  • 39 Downloads

Abstract

A 67-year-old female was referred to our hospital with a sternal fracture in March 2008. She received a diagnosis of multiple myeloma (MM) BJP-κ type (ISS stage III). G-banding karyotype revealed 46, XX, t(11;22)(q23.3;q11.2) (Hubacek, Gene 592:193–9, 2016), which was later confirmed to be congenital. After repeated rounds of chemotherapy with bortezomib and lenalidomide, she obtained a very good partial response in August 2014, and she was followed up with no treatment. However, she relapsed in February 2016. At that time, fluorescence in situ hybridization identified del(13q) and t(4;14)(p16;q32), which are associated with a poor prognosis. Furthermore, PCR analysis showed that the chromosome 11 breakpoint was at the APOA5/APOA4 locus at 11q23.3, which is associated with malignancy, and that the chromosome 22 breakpoint was at the SEPT5 intron 1 locus, which also plays a role in leukemogenesis through formation of a fusion gene with MLL. Although she was treated with three further lines of therapy, she died from disease progression in August 2017. Synergism between t(11;22) and t(4;14) may have induced the double-refractory phenotype to proteasome inhibitor and lenalidomide, at least during the chemorefractory phase. We present a biological analysis of this case and a review of the literature.

Keywords

Multiple myeloma Double refractory Congenital abnormality t(4;14) t(11;22) 

Notes

Author contributions

R.S. and K.A. analyzed the clinical status of the patient, analyzed the data, and prepared the manuscript. T.W., Y.N., Y.K., Y.A., Y.O., and H.K. analyzed the data.

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.

References

  1. 1.
    Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.CrossRefGoogle Scholar
  2. 2.
    Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324–39.CrossRefGoogle Scholar
  3. 3.
    Taylor TD, Noguchi H, Totoki Y, Toyoda A, Kuroki Y, et al. Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature. 2006;440:497–500.CrossRefGoogle Scholar
  4. 4.
    Yokoyama A. Transcriptional activation by MLL fusion proteins in leukemogenesis. Exp Hematol. 2017;46:21–30.CrossRefGoogle Scholar
  5. 5.
    Slany RK. The molecular mechanics of mixed lineage leukemia. Oncogene. 2016;35:5215–23.CrossRefGoogle Scholar
  6. 6.
    Zuo W, Wang SA, DiNardo C, Yabe M, Li S, et al. Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not MLL gene. J Clin Pathol. 2017;70:244–9.CrossRefGoogle Scholar
  7. 7.
    Leiba M, Duek A, Amariglio N, Avigdor A, Benyamini N, et al. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable? Genes Chromosomes Cancer. 2016;55:710–8.CrossRefGoogle Scholar
  8. 8.
    Cremer FW, Kartal M, Hose D, Bila J, Buck I, et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet Cytogenet. 2005;161:116–24.CrossRefGoogle Scholar
  9. 9.
    Delihas N. A family of long intergenic non-coding RNA genes in human chromosomal region 22q11.2 carry a DNA translocation breakpoint/AT-rich sequence. PLoS One. 2018;13:e0195702.CrossRefGoogle Scholar
  10. 10.
    Kurahashi H, Inagaki H, Hosoba E, Kato T, Ohye T, et al. Molecular cloning of a translocation breakpoint hotspot in 22q11. Genome Res. 2007;17:461–9.CrossRefGoogle Scholar
  11. 11.
    McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071.CrossRefGoogle Scholar
  12. 12.
    Hiroi N, Hiramoto T, Harper KM, Suzuki G, Boku S. Mouse models of 22q11.2-associated autism spectrum disorder. Autism Open Access Suppl. 2012;1:001.Google Scholar
  13. 13.
    Launay E, Henry C, Meyer C, Chappe C, Taque S, et al. MLL-SEPT5 fusion transcript in infant acute myeloid leukemia with t(11;22)(q23;q11). Leuk Lymphoma. 2014;55:662–7.CrossRefGoogle Scholar
  14. 14.
    Kurahashi H, Shaikh TH, Zackai EH, Celle L, Driscoll DA, et al. Tightly clustered 11q23 and 22q11 breakpoints permit PCR-based detection of the recurrent constitutional t(11;22). Am J Hum Genet. 2000;67:763–8.CrossRefGoogle Scholar
  15. 15.
    Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27:2165–76.CrossRefGoogle Scholar
  16. 16.
    Cerveira N, Bizarro S, Teixeira MR. MLL-SEPTIN gene fusions in hematological malignancies. Biol Chem. 2011;392:713–24.CrossRefGoogle Scholar
  17. 17.
    Hall PA, Russell SE. The pathobiology of the septin gene family. J Pathol. 2004;204:489–505.CrossRefGoogle Scholar
  18. 18.
    Ono R, Ihara M, Nakajima H, Ozaki K, Kataoka-Fujiwara Y, et al. Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4. Mol Cell Biol. 2005;25:10965–78.CrossRefGoogle Scholar
  19. 19.
    Guardiola M, Ribalta J. Update on APOA5 Genetics: toward a better understanding of its physiological impact. Curr Atheroscler Rep. 2017;19:30.CrossRefGoogle Scholar
  20. 20.
    Hubacek JA. Apolipoprotein A5 fifteen years anniversary: lessons from genetic epidemiology. Gene. 2016;592:193–9.CrossRefGoogle Scholar
  21. 21.
    Au A, Griffiths LR, Irene L, Kooi CW, Wei LK. The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke: evidence from a meta-analysis. Atherosclerosis. 2017;265:60–70.CrossRefGoogle Scholar
  22. 22.
    Major JM, Yu K, Weinstein SJ, Berndt SI, Hyland PL, et al. Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer. J Nutr. 2014;144:729–33.CrossRefGoogle Scholar
  23. 23.
    Chang SH, Luo S, Thomas TS, O’Brian KK, Colditz GA, et al. (2017) Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study. J Natl Cancer Inst 109.Google Scholar
  24. 24.
    Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, et al. Body fatness and cancer—viewpoint of the IARC working group. N Engl J Med. 2016;375:794–8.CrossRefGoogle Scholar
  25. 25.
    Morris EV, Edwards CM. (2018) Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma. J Cell PhysiolGoogle Scholar
  26. 26.
    Shah MY, Martinez-Garcia E, Phillip JM, Chambliss AB, Popovic R, et al. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene. 2016;35:5905–15.CrossRefGoogle Scholar
  27. 27.
    Kaseb HO, Lewis DW, Saunders WS, Gollin SM. Cell division patterns and chromosomal segregation defects in oral cancer stem cells. Genes Chromosomes Cancer. 2016;55:694–709.CrossRefGoogle Scholar
  28. 28.
    Li F, Zhai YP, Lai T, Zhao Q, Zhang H, et al. MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis. Oncotarget. 2017;8:51608–20.Google Scholar
  29. 29.
    Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 2008;111:3145–54.CrossRefGoogle Scholar
  30. 30.
    Pei H, Zhang L, Luo K, Qin Y, Chesi M, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 2011;470:124–8.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Hematology/OncologyTokai University School of MedicineIseharaJapan
  2. 2.Center for Regenerative MedicineTokai University School of MedicineIseharaJapan

Personalised recommendations